Biochemical and biophysical conditions for blood clot lysis.
We have studied how pharmacological dissolution of blood clots was affected by clot retraction, the mode of transport of fibrinolytic agents into the clot and the thickness of the composite fibrin fibers. Retracted clots were resistant to fibrinolysis in a milieu without dissolved plasminogen, because the amount of fibrin-bound plasminogen in retracted clots was insufficient for successful clot lysis. In plasma containing plasminogen, retracted clots were successfully lysed with fibrin-specific plasminogen activators, but not with non-fibrin-specific activators. Preincubation of retracted clots in plasma increased their plasminogen content as well as their sensitivity to fibrinolysis. The rate of lysis was increased up to 100-times when plasminogen activator and plasminogen were introduced into cylindrical clots by pressure-induced bulk flow in comparison with diffusion alone. The magnitude of the increase was similar in retracted and nonretracted clots, but the absolute rate of lysis was faster in non-retracted clots. The influence of fibrin fiber thickness on fibrinolysis was studied by atomic force microscopy. The time to complete lateral section of fibers did not differ between thick and thin composite fibers, and the rate of diameter reduction was faster in thick fibers than in thin ones. Taken together our results suggest that lysis of retracted clots proceeds in circular stages: (a) activation of bound plasminogen followed by partial degradation of fibrin, (b) opening of new plasminogen-binding sites on partly degraded fibrin, (c) binding of plasminogen to the new binding sites which enhances the susceptibility of clots to lysis. Lysis is accelerated by bulk flow of plasminogen activator and plasminogen into clots in comparison to diffusion alone. Fibrinolysis of thick composite fibrin fibers proceeds more efficiently than lysis of thin fibers.
Sabovic
M
M
Department of Vascular Medicine, University of Ljubljana Medical Center, Slovenia.
Blinc
A
A
D055592:Biophysical Phenomena; D001703:Biophysics; D055598:Chemical Phenomena; D002621:Chemistry; D005342:Fibrinolysis; D006801:Humans; D008279:Magnetic Resonance Imaging; D010958:Plasminogen / Q000008:administration & dosage / Q000032:analysis / Q000494:pharmacology; D010960:Plasminogen Activators / Q000008:administration & dosage / Q000494:pharmacology; D013927:Thrombosis / Q000097:blood*
D010958:Plasminogen; D010960:Plasminogen Activators